New combo therapy aims to wipe out rectal cancer before surgery
NCT ID NCT04928807
First seen Feb 28, 2026 · Last updated May 12, 2026 · Updated 12 times
Summary
This phase 3 trial tests whether a short course of radiation followed by immunotherapy (camrelizumab) and chemotherapy can completely eliminate rectal cancer before surgery. About 230 adults with locally advanced rectal cancer will be randomly assigned to this new approach or standard long-course chemoradiation. The main goal is to see if more patients have no cancer left in their removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Conditions
Explore the condition pages connected to this study.